Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;28(3):423-37.
doi: 10.1016/j.beem.2013.10.002. Epub 2013 Oct 17.

Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis

Lars Berglund  1 , John D Brunzell  2 , Anne C Goldberg  3 , Ira J Goldberg  4 , Anton Stalenhoef  5
Affiliations
Review

Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis

Lars Berglund et al. Best Pract Res Clin Endocrinol Metab. 2014 Jun.

Abstract

While there has been considerable focus on the role and treatment of LDL cholesterol levels, a definitive role of triglycerides in the management of cardiovascular disease has been uncertain. Notably, with increasing triglyceride levels, there is a parallel increase in cholesterol levels carried by triglyceride-rich lipoproteins, which has prompted interest in the use of non-HDL cholesterol levels as a tool guiding interventions. Recent studies have provided evidence for an independent role of triglyceride levels as a cardiovascular risk factor, and recently, an Endocrine Society guideline was published for treatment of hypertriglyceridemia. In contrast to the relative uncertainty regarding triglycerides and cardiovascular disease, a role of very high triglyceride levels as a risk factor for pancreatitis has been well known. The present paper summarizes the underlying evidence for a risk role for triglyceride levels in cardiovascular disease and pancreatitis, current treatment recommendations and areas of future research.

Keywords: coronary heart disease; dyslipidemia; hypolipidemic therapy; lifestyle intervention; lipoproteins.

PubMed Disclaimer

References

    1. Stamler J. Diet and coronary heart disease. Biometrics. 1982;38 (Suppl):95–118. - PubMed
    1. Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, et al. The seven countries study: 2,289 deaths in 15 years. Preventive medicine. 1984;13:141–154. - PubMed
    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed
    1. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The national cholesterol education program - adult treatment panel iii, international diabetes federation, and world health organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes care. 2007;30:8–13. - PubMed
    1. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation. 2002;106:3143–3421. - PubMed

MeSH terms